Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials

Neurology

Volumn 81, Issue 14, 2013, Pages 1215-1221

  Verhey, Leonard H ^a   Signori, Alessio ^b   Arnold, Douglas L ^c   Bar Or, Amit ^c   Sadovnick, A Dessa ^d   Marrie, Ruth Ann ^e   Banwell, Brenda ^f   Sormani, Maria Pia ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF GENOA   (Italy)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RELAPSE; SAMPLE SIZE; SCHOOL CHILD; SIMULATION; THERAPY EFFECT;

ADOLESCENT; BINOMIAL DISTRIBUTION; BRAIN; CHILD; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MODELS, STATISTICAL; MULTIPLE SCLEROSIS; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; RECURRENCE; RESEARCH DESIGN; SAMPLE SIZE; TIME FACTORS;

EID: 84888311932     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a6cb9b     Document Type: Article

References (32)

1. Pohl D, Waubant E, Banwell B, et al. Treatment of pediatric multiple sclerosis and variants. Neurology 2007;68: S54-S65. (Pubitemid 46626006)
2. Kuntz NL, Chabas D, Weinstock-Guttman B, et al. Treatment of multiple sclerosis in children and adolescents. Expert Opin Pharmacother 2010;11:505-520.
3. Ghezzi A, Banwell B, Boyko A, et al. The management of multiple sclerosis in children: A European view. Mult Scler 2010;16:1258-1267.
4. Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 2012;18:116-127.
5. Kappos L, Radue EW, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
6. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-1303.
7. Banwell B, Bar-Or A, Giovannoni G, Dale RC, Tardieu M. Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol 2011;7:109-122.
8. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
9. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
10. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68:1390-1401. (Pubitemid 46659091)
11. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294. (Pubitemid 26100751)
12. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995; 45:1268-1276.
13. Siri P, Henninger E, Sormani MP. A parametric model fitting time to first event for overdispersed data: Application to time to relapse in multiple sclerosis. Lifetime Data Anal 2012;18:139-156.
14. Sormani MP, Signori A, Siri P, De Stefano N. Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler 2013;19:466-474.
15. Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: A prospective national cohort study. Lancet Neurol 2011;10:436-445.
16. Verhey LH, Branson HM, Shroff MM, et al. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: A prospective national cohort study. Lancet Neurol 2011;10:1065-1073.
17. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007;68:S7-S12. (Pubitemid 46626001)
18. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
19. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489. (Pubitemid 43958540)
20. Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of no better explanation. Lancet Neurol 2006;5:841-852. (Pubitemid 44715819)
21. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: A consensus approach. Mult Scler 2008;14:1157-1174.
22. Sadaka Y, Verhey LH, Shroff MM, et al. 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol 2012;72:211-223.
23. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231. (Pubitemid 13158528)
24. Sormani MP, Bruzzi P, Miller DH, Gasperini C, Barkhof F, Filippi M. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci 1999; 163:74-80. (Pubitemid 29155420)
25. Sormani MP, Miller DH, Comi G, et al. Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J Neurol Neurosurg Psychiatry 2001;70:494-499. (Pubitemid 32269687)
26. Wang YC, Meyerson L, Tang YQ, Qian N. Statistical methods for the analysis of relapse data in MS clinical trials. J Neurol Sci 2009;285:206-211.
27. Francois M, Peter C, Gordon F. Dealing with excess of zeros in the statistical analysis of magnetic resonance imaging lesion count in multiple sclerosis. Pharm Stat 2012;11:417-424.
28. Sormani MP, Calabrese M, Signori A, Giorgio A, Gallo P, DeStefano N. Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studies. PLoS One 2011;6:e26712.
29. Giovannoni G, Comi G, Cook S, et al. A placebocontrolled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-426.
30. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009;66:54-59.
31. Bonzano L, Roccatagliata L, Mancardi GL, Sormani MP. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials? Mult Scler 2009;15:1043-1047.
32. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59:499-505.